Remove Branding Remove Doctors Remove FDA Approval
article thumbnail

Novo’s obesity drug has serious warnings and barriers to overcome

World of DTC Marketing

The headlines read “FDA approves obesity drug that helped people cut weight 15%” But buyer beware. The drug already exists at a lower dose as an anti-diabetic medication under the brand names Ozempic and Rybelsus made by the same pharmaceutical company, Novo Nordisk. appeared first on World of DTC Marketing.com.

Drugs 318
article thumbnail

Communicating with HCPs via email

World of DTC Marketing

SUMMARY: Doctors said they were dissatisfied were marketing emails (46%), telephone sales calls with sales reps (42%), and both webinars and websites (each at 39%) from pharma companies, according to Indegene. One of our tests, one of the most read emails, had a subject line of “new label information for prescribing just FDA approved.”

Doctors 180
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

When FDA-Approved Generics Fail: Brand Wellbutrin XL Antidepressant is Cheaper from Canada

Pharmacy Checkers

Many readers complained that it just wasn’t cutting it compared to the brand name version. I have reported this to the FDA and will be seeing my doctor this week. Apparently, the FDA had approved Budeprion XL 300mg after undergoing no actual testing. Just switch back to the brand!” Not normal, but better.

article thumbnail

The E-A-T of Disease Awareness and Why Brands Need to Get It Right

Intouch Solutions

you wouldn’t trust tax information on a recipe website), branded properties (i.e., brands should be seen as the authoritative sources for their own information), and being recommended by other experts. Similarly, pharma brands are their own entities, so the organizations behind these sites are never in question to Google or users.

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year. In addition, two more Humira biosimilars are currently under FDA review and both are anticipated to launch in 2023.

article thumbnail

Letybo Earns FDA Approval, Hugel Expands Its Global Aesthetic Market Leadership

XTalks

“We are thrilled with the FDA’s approval of Letybo. This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the US,” said James Hartman, president of Hugel America in the news release. “As Numerous doctors offer minimally invasive treatments aimed at reducing the visibility of frown lines.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Gilenya is an oral medication for multiple sclerosis.

Doctors 242